Search

Displaying results 2171 - 2180 of 4539 in total
  1. Drug

    Ribociclib

    go.drugbank.com/drugs/DB11730
    ApprovedInvestigational

    Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali. … Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).

  2. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    [A39743] In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. … Febuxostat works by inhibiting the activity of an enzyme that is responsible for the synthesis of uric acid, thereby reducing serum uric acid levels.

  3. Drug

    Misoprostol

    go.drugbank.com/drugs/DB00929
    ApprovedInvestigational

    Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions. The stimulation of prostaglandin receptors in the stomach...

  4. Drug

    Ancremonam

    go.drugbank.com/drugs/DB19710
    Investigational

    Ancremonam is under investigation in clinical trial NCT03377426 (LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)).

  5. Drug

    SGS-742

    go.drugbank.com/drugs/DB05010
    Investigational

    SGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.

  6. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide … This decision was supported by findings from the phase 3 SORAYA trial (NCT04296890).[L43967,L43972] It was subsequently granted full approval in March 2024.

  7. Drug

    Periciazine

    go.drugbank.com/drugs/DB01608
    Approved

    Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade.

  8. Drug

    Tixocortol

    go.drugbank.com/drugs/DB09091
    ApprovedWithdrawn

    Tixocortol is a 21-thiol derivative of hydrocortisone classified as a class A corticosteroid. It is a synthetic steroid with topical anti-inflammatory properties without the systemic glucocorticoid and mineralocorticoid activities and to...

  9. Drug

    Prednisolone acetate

    go.drugbank.com/drugs/DB15566
    ApprovedInvestigationalVet approved

    Prednisolone acetate is a [prednisolone] molecule bound to an acetate functional group by an ester bond.[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]

    Products: Ak Tate Oph Sus 1%
  10. Drug

    Siltuximab

    go.drugbank.com/drugs/DB09036
    ApprovedInvestigational

    MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. … Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6).